Status:

COMPLETED

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Kidney de Novo Transplant

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

All patients of the core study who are interested of being treated with EC-MPS will be included in an open-label extension study to collect further information on the long-term safety, tolerability an...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Male or female patients undergoing first kidney transplant.
  • Patients aged 18 -70 years.
  • Patients receiving an ABO identical or compatible graft. Exclusion Criteria
  • Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ other than kidney.
  • Positive HBsAg test
  • Pre-Transplant PRA \>50% or historical PRA \>75% Other protocol-defined inclusion/exclusion criteria may apply.

Exclusion

    Key Trial Info

    Start Date :

    December 1 2002

    Trial Type :

    INTERVENTIONAL

    End Date :

    Estimated Enrollment :

    144 Patients enrolled

    Trial Details

    Trial ID

    NCT00238992

    Start Date

    December 1 2002

    Last Update

    November 2 2011

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.